Impact of propofol sedation on the diagnostic accuracy of hepatic venous pressure gradient measurements in patients with cirrhosis.


Journal

Hepatology international
ISSN: 1936-0541
Titre abrégé: Hepatol Int
Pays: United States
ID NLM: 101304009

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 31 07 2021
accepted: 05 10 2021
pubmed: 27 10 2021
medline: 6 8 2022
entrez: 26 10 2021
Statut: ppublish

Résumé

Measurement of the hepatic venous pressure gradient (HVPG) is the gold standard to evaluate the presence and severity of portal hypertension. The procedure is generally safe and well tolerated, but nevertheless, some patients demand for sedation. However, it is unknown whether propofol sedation would impair the accuracy of portal pressure measurements. This is a prospective observational cohort study including cirrhotic patients with suspected portal hypertension undergoing invasive measurement of HVPG. Measurements of HVPG were performed in awake condition as well as under sedation with propofol infusion. In total, 37 patients were included. Mean HVPG in awake condition was 15.9 mmHg (IQR 13-19) and during sedation 14.1 mmHg (IQR 12-17). While measures of free hepatic vein pressure (FHVP) were not altered after propofol sedation (p = 0.34), wedged hepatic vein pressure values (WHVP) decreased in an average by  2.05 mmHg (95% CI - 2.46 to - 1.16; p < 0.001) which was proportional to the magnitude of HVPG. In 31 out of 37 patients (83.8%), portal hypertension with HVPG ≥ 12 mmHg was found. Under sedation with propofol, two patients (5.4%) with borderline values would have been incorrectly classified as < 12 mmHg. After adjustment for the average difference of - 10%, all patients were correctly classified. Intraclass correlation coefficient between HVPG measurement in awake condition and under propofol sedation was 0.927 (95% CI 0.594-0.975). Propofol sedation during HVPG measurements is generally safe, however it may lead to relevant alterations of HVPG readings.

Sections du résumé

BACKGROUND BACKGROUND
Measurement of the hepatic venous pressure gradient (HVPG) is the gold standard to evaluate the presence and severity of portal hypertension. The procedure is generally safe and well tolerated, but nevertheless, some patients demand for sedation. However, it is unknown whether propofol sedation would impair the accuracy of portal pressure measurements.
METHODS METHODS
This is a prospective observational cohort study including cirrhotic patients with suspected portal hypertension undergoing invasive measurement of HVPG. Measurements of HVPG were performed in awake condition as well as under sedation with propofol infusion.
RESULTS RESULTS
In total, 37 patients were included. Mean HVPG in awake condition was 15.9 mmHg (IQR 13-19) and during sedation 14.1 mmHg (IQR 12-17). While measures of free hepatic vein pressure (FHVP) were not altered after propofol sedation (p = 0.34), wedged hepatic vein pressure values (WHVP) decreased in an average by  2.05 mmHg (95% CI - 2.46 to - 1.16; p < 0.001) which was proportional to the magnitude of HVPG. In 31 out of 37 patients (83.8%), portal hypertension with HVPG ≥ 12 mmHg was found. Under sedation with propofol, two patients (5.4%) with borderline values would have been incorrectly classified as < 12 mmHg. After adjustment for the average difference of - 10%, all patients were correctly classified. Intraclass correlation coefficient between HVPG measurement in awake condition and under propofol sedation was 0.927 (95% CI 0.594-0.975).
CONCLUSIONS CONCLUSIONS
Propofol sedation during HVPG measurements is generally safe, however it may lead to relevant alterations of HVPG readings.

Identifiants

pubmed: 34699037
doi: 10.1007/s12072-021-10261-z
pii: 10.1007/s12072-021-10261-z
pmc: PMC9349095
doi:

Substances chimiques

Propofol YI7VU623SF

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

817-823

Informations de copyright

© 2021. The Author(s).

Références

Hepatology. 1999 Apr;29(4):1070-3
pubmed: 10094948
Anesth Analg. 1993 Oct;77(4 Suppl):S21-9
pubmed: 8214693
J Hepatol. 2021 Jul;75 Suppl 1:S49-S66
pubmed: 34039492
Lancet. 2003 Mar 15;361(9361):952-4
pubmed: 12648985
Hepatology. 2004 Feb;39(2):280-2
pubmed: 14767976
NMR Biomed. 2018 Oct;31(10):e3891
pubmed: 29369503
J Hepatol. 2006 Jan;44(1):217-31
pubmed: 16298014
Gastroenterology. 2007 Aug;133(2):481-8
pubmed: 17681169
PLoS One. 2013;8(1):e53311
pubmed: 23308191
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
Nat Rev Gastroenterol Hepatol. 2009 Oct;6(10):573-82
pubmed: 19724251
Expert Rev Gastroenterol Hepatol. 2018 Feb;12(2):155-164
pubmed: 28856972
Lancet. 1995 Oct 21;346(8982):1056-9
pubmed: 7564785
Gastroenterology. 1975 Dec;69(6):1297-300
pubmed: 1081459
Ann Transl Med. 2019 Oct;7(20):583
pubmed: 31807564
J Hepatol. 2019 Nov;71(5):942-950
pubmed: 31330170
Br J Anaesth. 2016 Jun;116(6):784-9
pubmed: 27199311
J Hepatol. 2014 Mar;60(3):561-9
pubmed: 24211744
J Pharm Pharmacol. 1989 Nov;41(11):797-8
pubmed: 2576054
Endoscopy. 2015 Dec;47(12):1175-89
pubmed: 26561915
Am J Respir Crit Care Med. 2002 Nov 15;166(10):1338-44
pubmed: 12421743
Hepatology. 2016 Dec;64(6):2173-2184
pubmed: 27639071
Liver Int. 2014 Jan;34(1):16-25
pubmed: 23763484
Semin Liver Dis. 2020 Aug;40(3):240-255
pubmed: 32557480
JGH Open. 2020 Dec 22;5(2):273-279
pubmed: 33553667

Auteurs

Fahim Ebrahimi (F)

Division of Gastroenterology and Hepatology, Clarunis University Center for Gastrointestinal and Liver Diseases, 4031, Basel, Switzerland.

David Semela (D)

Division of Gastroenterology and Hepatology, Kantonsspital, St. Gallen, 9007, St. Gallen, Switzerland.

Markus Heim (M)

Division of Gastroenterology and Hepatology, Clarunis University Center for Gastrointestinal and Liver Diseases, 4031, Basel, Switzerland. markus.heim@clarunis.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH